Clinical efficacy of laninamivir and peramivir in patients with seasonal influenza: a randomized clinical trial

Seo, Kazunori; Koga, Ichiro; Kitazawa, Takatoshi; Ota, Yasuo

doi:10.1080/23744235.2016.1242773

Cited by 8 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peramivir is a viable treatment option, especially in those patients in whom oral or inhaled antivirals are not the optimal route. 111,112 The pandemic 2009 H1N1 influenza strain was also notable for an increased frequency of NAI resistance in up to 14% of strains. 113 However, NAI resistance is currently uncommon, with an overall incidence of 0.5% to 1.9% of isolates, but does remain an area of growing concern.…”

Section: Treatmentmentioning

confidence: 99%

Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation

Paulsen

Danziger‐Isakov

2017

Clinics in Chest Medicine

View full text Add to dashboard Cite

Respiratory viruses are common in solid organ and hematopoietic stem cell transplant recipients and a recognized cause of significant morbidity and mortality. Epidemiology, risk factors, and attributable mortality in both populations are reviewed. In addition, virus-specific prevention and treatment options, including emerging investigational therapies, are discussed for respiratory syncytial virus, influenza, adenovirus, parainfluenza, and other respiratory viruses.

show abstract

Section: Treatmentmentioning

confidence: 99%

Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation

Paulsen

Danziger‐Isakov

2017

Clinics in Chest Medicine

View full text Add to dashboard Cite

show abstract

“…After literature search (Figure 1), we identified 14 studies that were potentially eligible for our metaanalysis [18][19][20][21][22][23][24][25][26][27][28][29][30][31]. One study that evaluated the efficacy of laninamivir octanoate on a treatment setting was removed because the time to event was not precisely evaluated [30].…”

Section: Analysed Studiesmentioning

confidence: 99%

A Meta-Analysis of Laninamivir Octanoate for Treatment and Prophylaxis of Influenza

2017

View full text Add to dashboard Cite

Overall, the efficacy of laninamivir octanoate in treating influenza was comparable to that of oseltamivir or zanamivir, but it should be noted that laninamivir octanoate was associated with significantly longer fever duration in treating influenza H3N2 as compared to oseltamivir and oseltamivir-resistant mutations in seasonal influenza H1N1 might have affected the results. Peramivir may be superior to laninamivir in treating influenza. Laninamivir octanoate is effective in preventing influenza in post-exposure settings as compared to placebo.

show abstract

“…Finally, high heterogeneity was observed in time to alleviation of all symptoms in our meta-analysis; thus, we performed sensitivity analysis. The heterogeneity significantly reduced after excluding two studies [26,31], and the result still favored the efficacy of peramivir. Yoshino applied ≤37 • C as the threshold of fever resolution; however, most studies used thresholds ranging from ≤37.5 • C to ≤38 • C. Clarifying this difference might be difficult because our included studies did not report the method of measurement.…”

Section: Discussionmentioning

confidence: 96%

“…All articles compared peramivir with at least one NAI. Five trials [21][22][23][24][25] compared peramivir with oseltamivir only, two trials [26,27] compared peramivir with oseltamivir and laninamivir, and five trials [28][29][30][31][32] compared peramivir with oseltamivir, laninamivir, and zanamivir. The risk of bias in most studies was low (Tables 1 and 2) and the quality of most outcomes was moderate ( Table 3).…”

Section: Study Search Outcomes and Included Patientsmentioning

confidence: 99%

See 1 more Smart Citation

A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment

et al. 2020

View full text Add to dashboard Cite

Background and Objectives: This meta-analysis compared the efficacy and safety of peramivir compared to other neuraminidase inhibitors (NAIs). Materials and Methods: Data from PubMed, Embase, and Cochrane databases and ClinicalTrials.gov were searched until January 2019. Randomized controlled trials (RCTs) and observational studies (OSs) comparing peramivir with other NAIs for treating influenza were included. The Grading of Recommendations, Assessments, Development, and Evaluations (GRADE) system was used to judge the overall certainty of evidence; the result was moderate. The primary outcome was time to alleviation of symptoms. Twelve articles involving 2681 patients were included in this meta-analysis. We used a random-effect model to pool the effect size, which is expressed as the difference in means (MD), risk ratio (RR), and 95% confidence interval (CI). Results: Overall, peramivir was superior to other NAIs (MD = −11.214 hours, 95% CI: −19.119 to −3.310). The incidence of adverse events (RR = 1.023, 95% CI: 0.717 to 1.460) and serious adverse events (RR = 1.068, 95% CI: 0.702 to 1.625) in the peramivir group was similar to those in the oseltamivir group. In addition, peramivir had higher efficacy than each NAI alone. Conclusion: In conclusion, the efficacy of peramivir might be higher than that of other NAIs, and this agent is tolerated as well as other NAIs.

show abstract

Clinical efficacy of laninamivir and peramivir in patients with seasonal influenza: a randomized clinical trial

Cited by 8 publications

References 10 publications

Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation

Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation

A Meta-Analysis of Laninamivir Octanoate for Treatment and Prophylaxis of Influenza

A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment

Contact Info

Product

Resources

About